Advanced Search
Contact | Corporate | Help

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Sponsors:
  • Novartis Pharmaceuticals
  • Genentech
Phases:
  • Phase IV
IndicationsAcronym:
  • Asthma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: omalizumab at a dose of 0.016mg/kg/IU/mL
  • Drug: Placebo
Enrollment:
67

Additional information about NCT00670930.


SourceSolution © 2008-2012